The possible mechanism of idiosyncratic lapatinib-induced liver injury in patients carrying human leukocyte antigen-DRB1∗07:01

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Hirasawa, Makoto ^a   Hagihara, Katsunobu ^a   Okudaira, Noriko ^a   Izumi, Takashi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DRB1 ANTIGEN; LAPATINIB; TETANUS TOXOID; HLA-DRB1*07:01:01 ANTIGEN; QUINAZOLINE DERIVATIVE;

ANTIGEN BINDING; ANTIGEN STRUCTURE; ARTICLE; BETA CHAIN; COMPUTER MODEL; CONTROLLED STUDY; HUMAN; IN VITRO STUDY; LIGAND BINDING; LIVER INJURY; MOLECULAR DYNAMICS; PATHOGENESIS; CHEMISTRY; METABOLISM; MOLECULAR MODEL; PATHOPHYSIOLOGY; TOXIC HEPATITIS;

CHEMICAL AND DRUG INDUCED LIVER INJURY; HLA-DRB1 CHAINS; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; QUINAZOLINES; TETANUS TOXOID;

EID: 84939205267     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130928     Document Type: Article

References (19)

1. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355:2733-2743. PMID: 17192538
2. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009; 27:5538-5546. doi: 10.1200/JCO.2009.23.3734 PMID: 19786658
3. Moy B, Rappold E, Williams L, Kelly T, Nicolodi L, Maltzman JD, et al. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. J Clin Oncol. 2009; 27(51s):1043. (abstr)
4. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, et al. HLA-DQA1∗02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011; 29:667-673. doi: 10.1200/JCO.2010.31.3197 PMID: 21245432
5. Spraggs CF, Parham LR, Hunt CM, Dollery CT. Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes. Clin Pharmacol Ther 2012; 91(4):647-52. doi: 10.1038/clpt.2011.277 PMID: 22357454
6. Schaid DJ, Spraggs CF, McDonnell SK, Parham LR, Cox CJ, Ejlertsen B, et al. Prospective validation of HLA-DRB1∗07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J Clin Onco. 2014; 32(22):2296-303. doi: 10.1200/JCO.2013.52.9867 PMID: 24687830
7. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008; 8:186-195. PMID: 17505501
8. Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med. 2006; 203:961-71. PMID: 16585267
9. Huey R, Morris GM, Olson AJ, Goodsell DS A semiempirical free energy force field with charge-based desolvation. J Comput Chem. 2007; 28(6):1145-52. PMID: 17274016
10. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010; 31(2):455-61. doi: 10.1002/jcc.21334 PMID: 19499576
11. Zaheer-ul-Haq, Khan W. Molecular and structural determinants of adamantyl susceptibility to HLA-DRs allelic variants: an in silico approach to understand the mechanism of MLEs. J Comput Aided Mol Des. 2011; 25(1):81-101. doi: 10.1007/s10822-010-9404-y PMID: 21116684
12. Norcross MA, Luo S, Lu L, Boyne MT, Gomarteli M, Rennels AD, et al. Abacavir induces loading of novel self-peptides into HLA-B∗57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS. 2011; 26(11):F21-9. doi: 10.1097/QAD.0b013e328355fe8f PMID: 22617051
13. Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev. 2013; 65(2):779-808 doi: 10.1124/pr.113.007450 PMID: 23476052
14. Padovan E, Bauer T, Tongio MM, Kalbacher H, Weltzien HU. Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy.Eur J Immunol.1997; 27(6):1303-7. PMID: 9209477
15. Pichler WJ, Beeler A, Keller M, Lerch M, Posadas S, Schmid D, et al. Pharmacological interaction of drugs with immune receptors: the p-i concept. Allergol Int. 2006; 55(1):17-25. PMID: 17075282
16. Höpner S, Dickhaut K, Hofstätter M, Krämer H, Rückerl D, Söderhäll JA, et al. Small Organic Compounds Enhance Antigen Loading of Class II Major Histocompatibility Complex Proteins by Targeting the Polymorphic P1 Pocket. J Biol Chem. 2006; 281(50):38535-42. PMID: 17005558
17. Gupta S, Höpner S, Rupp B, Günther S, Dickhaut K, Agarwal N, et al. Anchor Side Chains of Short Peptide Fragments Trigger Ligand-Exchange of Class II MHC Molecules. PLoS ONE. 2008; 3(3):e1814. doi: 10.1371/journal.pone.0001814 PMID: 18350151
18. Michels AW, Ostrov DA, Zhang L, Nakayama M, Fuse M, McDaniel K, et al. Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. J Immunol. 2011; 187(11):5921-30. doi: 10.4049/jimmunol.1100746 PMID: 22043012
19. Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature. 2012; 486(7404):554-8. doi: 10.1038/nature11147 PMID: 22722860